NCT03309592View on ClinicalTrials.gov

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 12, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Portopulmonary HypertensionPulmonary HypertensionCirrhosis, Liver
Interventions
DRUG

Ambrisentan Pill

Will be administered as stated in Arm/Group Descriptions

DRUG

Tadalafil Pill

Will be administered as stated in Arm/Group Descriptions

Trial Locations (1)

70121

Ochsner Clinic Foundation, New Orleans

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Ochsner Health System

OTHER